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Orexin receptor antagonists represent attractive targets for the development of drugs
for the treatment of insomnia. Both efficacy and safety are crucial in clinical settings
and thorough investigations of pharmacokinetics and pharmacodynamics can predict
contributing factors such as duration of action and undesirable effects. To this end, we
studied the interactions between various “dual” orexin receptor antagonists and the
orexin receptors, OX1R and OX2R, over time using saturation and competition radioligand
binding with [3H]-BBAC ((S)-N-([1,1′-biphenyl]-2-yl)-1-(2-((1-methyl-1H-benzo[d]imidazol-2-
yl)thio)acetyl)pyrrolidine-2-carboxamide). In addition, the kinetics of these compounds
were investigated in cells expressing human, mouse and rat OX1R and OX2R using FLIPR®
assays for calcium accumulation. We demonstrate that almorexant reaches equilibrium
very slowly at OX2R, whereas SB-649868, suvorexant, and filorexant may take hours to
reach steady state at both orexin receptors. By contrast, compounds such as BBAC or the
selective OX2R antagonist IPSU ((2-((1H-Indol-3-yl)methyl)-9-(4-methoxypyrimidin-2-yl)-2,9-
diazaspiro[5.5]undecan-1-one) bind rapidly and reach equilibrium very quickly in binding
and/or functional assays. Overall, the “dual” antagonists tested here tend to be rather
unselective under non-equilibrium conditions and reach equilibrium very slowly. Once
equilibrium is reached, each ligand demonstrates a selectivity profile that is however,
distinct from the non-equilibrium condition. The slow kinetics of the “dual” antagonists
tested suggest that in vitro receptor occupancy may be longer lasting than would be
predicted. This raises questions as to whether pharmacokinetic studies measuring plasma
or brain levels of these antagonists are accurate reflections of receptor occupancy in vivo.
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INTRODUCTION
The orexin receptors, OX1R and OX2R, were deorphanised in
1998, when two independent teams identified the peptides orexin
A and orexin B (de Lecea et al., 1998; Sakurai et al., 1998).
OX1R and OX2R are G protein-coupled receptors that share 64%
amino acid sequence identity in humans and are highly conserved
between species (de Lecea et al., 1998; Sakurai et al., 1998). Both
Abbreviations: 5-HT, serotonin; BBAC, (S)-N-([1,1′-biphenyl]-2-yl)-1-(2-((1-
methyl-1H-benzo[d]imidazol-2-yl)thio)acetyl)pyrrolidine-2-carboxamide; BSA,
Bovine Serum Albumin; cAMP, cyclic AMP; CHO, Chinese Hamster Ovary;
DMEM, Dulbecco’s Modified Eagle’s Medium; F12, Ham’s F12 nutrients mix-
ture; FDA, Federal Drug Administration of the United States Department of
Health and Human Services; FLIPR®, FLuorescent Imaging Plate Reader; GABA,
γ-aminobutyric acid; HEK, Human Embryonic Kidney; IPSU, 2-((1H-Indol-3-
yl)methyl)-9-(4-methoxypyrimidin-2-yl)-2,9-diazaspiro[5.5]undecan-1-one; KO,
Knock Out; NSB, Non-specific Binding; OX1R, orexin receptor 1; OX2R, orexin
receptor 2; REM, Rapid Eye Movement (sleep state).
receptors can couple to Gq and mobilize intracellular Ca2+ via
activation of phospholipase C (Sakurai et al., 1998), whilst OX2R
can also couple Gi/Go and inhibit cAMP production via inhibi-
tion of adenylate cyclase (Zhu et al., 2003). In non-neuronal cells
OX2R is capable of extracellular signal-regulated kinase activation
via Gs, Gq, and Gi (Tang et al., 2008). In competition radioli-
gand binding OX1R has a 10–100 fold higher affinity for orexin
A (20 nM) than for orexin B (250 nM), whereas OX2R binds both
orexin peptides with similar affinity (Sakurai et al., 1998).
Orexin is exclusively expressed by orexin producing neu-
rons within the perifornical nucleus, the dorsomedial hypotha-
lamic nucleus, and the dorsal and lateral hypothalamic areas
(Peyron et al., 1998). Orexin producing neurons are limited
to a few thousand in rodents, whereas in humans there are
approximately 30,000–70,000. These neurons have both ascend-
ing and descending projections with dense projections to key
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nuclei of the ascending arousal system such as the adrenergic
locus coeruleus, the serotonergic dorsal raphe, and the histamin-
ergic tuberomammillary nucleus. These same regions also receive
inhibitory projections from the ventrolateral preoptic area, which
promote sleep (Sherin et al., 1998).
The orexin receptors are widely distributed in the brain in a
pattern consistent with orexin neuron projections (Trivedi et al.,
1998;Marcus et al., 2001). Although the expression patterns of the
receptors are largely overlapping, OX1R is selectively expressed
in the locus coeruleus and OX2R is expressed in the tubero-
mammillary nucleus. The broad distribution of the orexin system
throughout the cortex, hippocampus, thalamic, and hypothala-
mic nuclei suggests it may modulate a variety of functions includ-
ing arousal, appetite, metabolism, reward, stress, and autonomic
function (Scammell and Winrow, 2011; Gotter et al., 2012).
Although orexin was originally named for its role in feed-
ing behavior (Sakurai et al., 1998), the link between energy
homeostasis and sleep/wakefulness is increasingly recognized
(Yamanaka et al., 2003) and it is clear that the orexin system
is crucial for the stability of wake and sleep states (Sakurai,
2007). The orexin system was first linked to the sleep disorder
narcolepsy: a mutation in the OX2R gene was found to cause
canine narcolepsy (Lin et al., 1999) and the knockout (KO) of
orexin peptides in mice also resulted in narcolepsy with cata-
plexy (Chemelli et al., 1999). Indeed, several orexin system KO
and transgenic models exhibit sleep abnormalities reminiscent of
narcolepsy (Chemelli et al., 1999; Hara et al., 2001a,b; Willie et al.,
2003; Beuckmann et al., 2004). The absence of orexin neurons
or peptides and the double receptor KO mouse models reca-
pitulate the human narcoleptic symptoms, with narcoleptic and
cataplectic phenotypes, whereas single orexin receptor KO mice
have only a moderate (OX2R) or no sleep phenotype (OX1R)
(Chemelli et al., 1999; Scammell et al., 2000; Hara et al., 2001a,b;
Beuckmann et al., 2002; Willie et al., 2003; Kalogiannis et al.,
2011).
Narcolepsy with cataplexy is associated with severe daytime
sleepiness (Tafti et al., 2005) due to the complete disorganiza-
tion of the sleep/wake cycle, with sudden onset of Rapid Eye
Movement (REM) sleep and cataplexy (loss of skeletal muscle
tone without the loss of consciousness triggered by emotions).
Patients with narcolepsy have undetectable levels of orexin in
cerebral spinal fluid (Nishino et al., 2000) and a marked decrease
in orexin producing cells in the hypothalamus (Thannickal et al.,
2000). The cause of human narcolepsy is neurodegeneration
of orexin-containing neurons, possibly due to an autoimmune
disease (Tafti, 2007), although the precise mechanism is not
established.
Not surprisingly, the orexin system has attracted substan-
tial attention for the development of drugs for the treatment
of insomnia. Dual orexin receptor antagonists or possibly selec-
tive OX2R antagonists are likely to be effective without some
of the undesirable side effects of currently available treat-
ments. Benzodiazepines and sedative hypnotics are commonly
prescribed and inhibit arousal through activation or positive
allosteric modulation of the GABAA receptor. However, reported
side effects include morning sedation, anxiety, anterograde
amnesia, impaired balance and sleep behaviors such as sleep
walking and eating (Buysse, 2013).
A number of orexin receptor antagonists have been devel-
oped that are expected to have advantages over classic sleep
promoting drugs (see Uslaner et al., 2013). These have been
reported as “dual” antagonists as they have apparently similar
affinities for both OX1R and OX2R (Roecker and Coleman, 2008;
Scammell and Winrow, 2011). Almorexant was the first com-
pound for which clinical data was reported in volunteers and
patients (Brisbare-Roch et al., 2007; Malherbe et al., 2009; Owen
et al., 2009) followed closely by SB-649868 (also known as GW
649868) (Bettica et al., 2009a,b, 2012a,b,c), suvorexant, the most
advanced antagonist that has successfully completed phase III
clinical trials (Cox et al., 2010; Winrow et al., 2011; Connor et al.,
2012; Herring et al., 2012b; Ivgy-May et al., 2012) and filorexant
(Coleman et al., 2012; Winrow et al., 2012). Also in this issue,
we present our characterization of IPSU (Hoyer et al., 2013), an
orally bioavailable, brain penetrant OX2R antagonist, on sleep
architecture in mice.
During the characterization of orexin receptor antagonists, we
and others (Malherbe et al., 2010; Mang et al., 2012; Morairty
et al., 2012) have noticed that almorexant has peculiar kinetic
features, in particular a very slow dissociation rate constant
especially at OX2R. Such features may be clinically relevant as
they influence duration of action and potential for side effects.
Therefore, we performed kinetic studies on the dual orexin recep-
tor antagonists listed above in comparison with BBAC (Figure 1)
and/or IPSU in radioligand binding and signaling studies at both
OX1R and OX2R.
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
[3H]-BBAC ((S)-N-([1,1′-biphenyl]-2-yl)-1-(2-((1-methyl-1H-
benzo[d]imidazol-2-yl)thio)acetyl)pyrrolidine-2-carboxamide,
Specific activity 73.76Ci/mmol) was synthesized at Novartis
Pharma AG Basel (Isotope Laboratories). BBAC, SB-649868,
suvorexant, filorexant, and IPSU (2-((1H-Indol-3-yl)methyl)-9-
(4-methoxypyrimidin-2-yl)-2,9-diazaspiro[5.5]undecan-1-one)
were synthesized at Novartis Pharma AG. Almorexant was
synthesized by Anthem Biosciences (Bangalore, India).
FIGURE 1 | Chemical structure of BBAC ((S)-N-([1,1′-biphenyl]-2-yl)-1-
(2-((1-methyl-1H-benzo[d]imidazol-2-yl)thio)acetyl)pyrrolidine-2-
carboxamide).
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CELL CULTURE AND CELL MEMBRANE PREPARATION
Chinese Hamster Ovary (CHO) cells stably transfected with
the cDNA encoding the human OX1R (CHO-hOX1) or OX2R
(CHO-hOX2) were used (kindly provided by T. Cremer and Dr.
S. Geisse, NIBR Basel, Switzerland). For measurements of cal-
cium accumulation using FLIPR® (Fluorescent Imaging Plate
Reader) assay, CHO or Human Embryonic Kidney (HEK) cells
stably expressing mouse, rat or human OX1R or OX2R (kindly
provided by Dr. A. Chen, GNF, San Diego, CA, USA) were
used. All cells were cultured in 1:1 Dulbecco’s Modified Eagle’s
Medium (DMEM)/Ham’s F12 Nutrients Mixture (F12) supple-
mented with 10% (v/v) fetal bovine serum (FBS), 100μ/ml
(100 g/ml)/streptomycin (100μg/ml), Fungizone (250μg/ml),
and Geneticin (G418, 50mg/ml). Cells were maintained in a
humidified incubator at 37◦C in 5% CO2. For crude cell mem-
brane preparations, cells were washed and harvested in 10mM
HEPES (pH 7.5), and centrifuged at 4◦C for 5min at 2500 g. The
cell pellet was either stored at −80◦C or used directly.
RADIOLIGAND BINDING ASSAYS
Cell membranes were resuspended in binding assay buffer at
4◦C (10mM HEPES, pH 7.5, 0.5% (w/v) bovine serum albu-
min (BSA), 5mM MgCl2, 1mM CaCl2, and 0.05% Tween 20)
and homogenized with a Polytron homogenizer at 50Hz for 20 s.
Cells were incubated with [3H]-BBAC in binding assay buffer in
96-deep well plates (Fisher Scientific). Aliquots of [3H]-BBAC
were measured using liquid scintillation spectrometry on a LS
6500 scintillation counter (Beckman Coulter) to determine the
amount radioactivity added to each well. Non-specific Binding
(NSB) was determined in the presence of 1μM almorexant.
After the indicated incubation time, bound and free radioligand
were separated by vacuum filtration using a Filtermate™ Cell
Harvester (Perkin Elmer) and filtered onto 96-well deep GF/b fil-
ter plates (Millipore) which had been pre-treated with 0.5% (w/v)
polyethyleneimine. Filter plates were rapidly washed three times
with wash buffer (10mM Tris-HCl, 154mM NaCl, pH 7.4) at
4◦C, dried and 25μl of Microscint™ (Perkin Elmer) was added
to each well. Radioactivity was quantified using a TopCount™
microplate counter (Perkin Elmer).
SATURATION BINDING
Binding was performed with eight concentrations of [3H]-BBAC
(50μl, 1–20 nM) to construct saturation curves. CHO-hOX1 or
CHO-hOX2 cell membranes (150μl/well) were incubated for
60min in 96-deep well plates at room temperature with radioli-
gand in binding assay buffer (50μl) in the presence or absence
of almorexant (1μM, 50μl), in a final volume of 250μl. [3H]-
BBAC binding was measured in triplicate in at least three inde-
pendent experiments. Data in the figures is representative of the
mean ± s.e.m. of a single experiment.
COMPETITION BINDING
Competition experiments were performed with a single con-
centration of radioligand and six concentrations of competitor
(unlabeled ligands; BBAC, almorexant, SB-649868, suvorexant,
filorexant or IPSU). 4.6 nM [3H]-BBAC (chosen from satura-
tion experiments to provide 80–90% specific binding, 50μl) was
added simultaneously with various concentrations of unlabeled
ligand (0.1 nM–10μM) to membranes (150μl/well) in 50μl/well
of assay buffer with a total volume of 250μl/well. The amount
of [3H]-BBAC bound to receptors was determined at room tem-
perature at different time points (ranging from 15min to 4 h)
and terminated by rapid vacuum filtration and liquid scintilla-
tion counting. Binding at a given concentration of competitor at
a given time was measured in triplicate in at least three indepen-
dent experiments. Data in figures is representative of the mean ±
s.e.m. of a single experiment.
DATA ANALYSIS
All data was analyzed using GraphPad Prism 4.0 (GraphPad, San
Diego, USA). The saturation data was fit to a non-linear regres-
sion model for saturation binding with consideration for one
site binding. In addition, saturation binding data was also ana-
lyzed according to Scatchard (Scatchard, 1949; plots not shown).
Competition binding data was fit to a non-linear regression
model for competition binding with consideration for variable
one site binding with a non-fixed Hill slope. The method of
Cheng and Prusoff (1973) was used to convert IC50 values from
competition binding curves to Ki (equilibrium dissociation con-
stant) values.
FUNCTIONAL ANALYSIS OF DUAL ANTAGONISTS ON HUMAN OREXIN
RECEPTORS
Determination of orexin A-stimulated calcium accumulation
was performed over 2 days using FLIPR® (Fluorescent imaging
plate reader fromMolecular Devices-FLIPR384). Cells expressing
either human, rat or mouse OX1R or OX2R were seeded at 8,000
cells/well in black 384 well clear bottom plates and incubated
overnight at 37◦C. The following day, medium was discarded
and cells loaded with 50μl of 1mM Fluo-4 AM (Invitrogen
F14202) in dimethyl sulfoxide in working buffer (Hanks’ bal-
anced salt solution, 10mM HEPES) and incubated for 60min at
37◦C. The loading buffer was removed and cells were washed with
100μl working buffer containing 200mM CaCl2, 0.1% BSA, and
2.5mM Probenecid (pH 7.4) to remove the excess Fluo-4 AM.
Working buffer was added and plates were incubated 10–15min
at room temperature. The assay plate was then transferred to the
Molecular Devices-FLIPR384. The baseline calcium signal was
recorded for 10 s, then the antagonist of interest was injected
(10μl at 3 times the final concentration) and the calcium signal
recorded every second for 1min, then every 2 s 40 times. Plates
were then incubated at room temperature for 30min, 1, 2, or 4 h.
Calcium signals were again measured as above, this time orexin A
(15μl) was injected at 3 times the final concentration. For each
experiment, full orexin A concentration response curves were
generated on each plate: they served to calculate the EC50 for that
plate and to adapt the EC80 values in the subsequent experiments,
which vary according to cell line and passage number.
The concentration response curves were analyzed according to
the law of mass action, for both orexin A (EC50), and antago-
nists (IC50) with slope factors and maximal/minimal effects; the
antagonist data was transformed according to Cheng and Prusoff
(1973) (Ki = IC50/1 = (L/EC50)) where L is the agonist con-
centration used in the assay and EC50 its concentration for half
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maximal activation and the antagonist data was finally expressed
as Ki (nM) and pKi values (−log M).
RESULTS
TIME-DEPENDENT CHANGES IN APPARENT AFFINITY AS
DETERMINED IN RADIOLIGAND BINDING
[3H]-BBAC bound both OX1R and OX2R with high affinity
and KD values of about 7 nM and 1 nM, respectively (Figure 2).
Binding reached equilibrium very quickly, as 15–30min incuba-
tion time was sufficient to reach Bmax and KD values comparable
to those measured after 4 h (data not shown).
Competition experiments were performed with the various
antagonists at 15, 30, 45min, 1, 2, or 4 h and the graphs illus-
trate the competition curves at the different times. As expected
from the saturation experiments described above, as well as in fur-
ther kinetic experiments to be reported elsewhere, BBAC reached
equilibrium quickly at both OX1R and OX2R (15–30min), and
there was no significant difference in IC50 values measured
between 30min and 4 h, as illustrated by superimposable com-
petition curves at both orexin receptors (Figure 3).
In contrast to BBAC, the competition curves for almorexant
shifted to the left with time moderately at OX1R and substantially
at OX2R (Figure 4). In other words, almorexant showed simi-
lar apparent affinity at OX1R between 30min and 4 h, whereas
FIGURE 2 | Saturation binding of [3H]-BBAC ((S)-N-([1,1′-biphenyl]-
2-yl)-1-(2-((1-methyl-1H-benzo[d]imidazol-2-yl)thio)acetyl)pyrrolidine-2-
carboxamide) to membranes from CHO cells expressing human (A)
OX1R or (B) OX2R. Almorexant was used to define non-specific binding
(blue). Total binding is indicated in red and specific binding in green. Data is
representative of triplicate determinations and error bars indicate s.e.m.
FIGURE 3 | Effect of time on BBAC ((S)-N-([1,1′-biphenyl]-2-yl)
-1-(2-((1-methyl-1H-benzo[d]imidazol-2-yl)thio)acetyl)pyrrolidine-2-
carboxamide) competition for [3H]-BBAC binding to membranes from
CHO cells expressing human (A) OX1R or (B) OX2R. Data is
representative of triplicate determinations and error bars indicate s.e.m.
the apparent affinity at OX2R increased up to 4 h of incubation.
The data suggests that equilibrium at OX2R can only be reached
after prolonged incubation, which also means that under short
term conditions, almorexant is a dual orexin receptor antagonist,
whereas after several hours of exposure, the compound becomes
somewhat OX2R selective.
The SB-649868 competition curves on OX1R shifted to the
left over time up to 4 h, whereas at OX2R binding appeared to
be rather stable (Figure 5), suggesting that the compound equili-
brated very rapidly at OX2R whereas it took hours to equilibrate
at OX1R. This means that although acting as a dual antagonist
acutely, given sufficient time to equilibrate, SB-649868 will show
some OX1R selectivity.
Similarly, the suvorexant competition curves for both OX1R
and OX2R shifted to the left over time, although the effect on
OX2R was somewhat less pronounced (Figure 6). Thus, suvorex-
ant equilibrates slowly at both orexin receptors and since equi-
librium is generally driven by the dissociation rate constant,
this means that once steady state binding is reached, receptor
occupancy will be long lasting.
The filorexant competition curves at OX1R were rather insen-
sitive to incubation time, whereas OX2R curves shifted to the left
over time, even up to 4 h (Figure 7). Thus, similar to the other
dual orexin receptor antagonists tested here, filorexant reaches
equilibrium only after several hours of incubation, especially at
OX2R.
FIGURE 4 | Effect of time on almorexant competition for [3H]-BBAC
((S)-N-([1,1′-biphenyl]-2-yl)-1-(2-((1-methyl-1H-benzo[d]imidazol-2-
yl)thio)acetyl)pyrrolidine-2-carboxamide) binding to membranes from
CHO cells expressing human (A) OX1R or (B) OX2R. Data is
representative of triplicate determinations and error bars indicate s.e.m.
FIGURE 5 | Effect of time on SB-649868 competition for [3H]-BBAC
((S)-N-([1,1′-biphenyl]-2-yl)-1-(2-((1-methyl-1H-benzo[d]imidazol-2-
yl)thio)acetyl)pyrrolidine-2-carboxamide) binding to membranes from
CHO cells expressing human (A) OX1R or (B) OX2R. Data is
representative of triplicate determinations and error bars indicate s.e.m.
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The IPSU competition curves at OX1R and OX2R do not
show time-dependency (Figure 8), since maximal inhibition was
already achieved following 15min of incubation. This suggests a
very rapid binding and equilibrium and a tendency to a rightward
shift, suggesting faster kinetics than for the radioligand.
TIME-DEPENDENT CHANGES IN APPARENT AFFINITY AS
DETERMINED IN CALCIUM ASSAYS
In the calcium accumulation assays performed at mouse, rat
and human OX1R and OX2R, we first confirmed that orexin A
produces stable results and that the apparent potency is largely
FIGURE 6 | Effect of time on suvorexant competition for [3H]-BBAC
((S)-N-([1,1′-biphenyl]-2-yl)-1-(2-((1-methyl-1H-benzo[d]imidazol-2-
yl)thio)acetyl)pyrrolidine-2-carboxamide) binding to membranes from
CHO cells expressing human (A) OX1R or (B) OX2R. Data is
representative of triplicate determinations and error bars indicate s.e.m.
FIGURE 7 | Effect of time on filorexant competition for [3H]-BBAC
((S)-N-([1,1′-biphenyl]-2-yl)-1-(2-((1-methyl-1H-benzo[d]imidazol-2-
yl)thio)acetyl)pyrrolidine-2-carboxamide) binding to membranes from
CHO cells expressing human (A) OX1R or (B) OX2R. Data is
representative of triplicate determinations and error bars indicate s.e.m.
FIGURE 8 | Effect of time on IPSU competition for [3H]-BBAC
((S)-N-([1,1′-biphenyl]-2-yl)-1-(2-((1-methyl-1H-benzo[d]imidazol-2-
yl)thio)acetyl)pyrrolidine-2-carboxamide) binding to membranes from
CHO cells expressing human (A) OX1R or (B) OX2R. Data is
representative of triplicate determinations and error bars indicate s.e.m.
comparable when the effects of antagonists are measured fol-
lowing incubation times of between 30min and 4 h. Indeed,
pEC50 values for orexin were largely time-independent at both
OX1R and OX2R. This suggests the cells and receptors used were
stable and would allow incubation times of up to 4 h in the
subsequent experiments (Tables 1, 2). At OX1R, almorexant had
an apparent antagonist potency which was constant, irrespec-
tive of the incubation time (30min–4 h, Table 1). By contrast,
at OX2R, the apparent potency kept increasing with incubation
time (Table 2), as suggested by the radioligand binding experi-
ments. These results indicate that across the three species studied
here there is an apparent OX2R selectivity after longer incubation
times. Filorexant showed time-independent potencies at OX1R,
whereas at OX2R the apparent potencies increased with time.
Suvorexant showed a time-dependent shift toward higher potency
as time increased at both receptors, although the effects were
more pronounced at OX2R. For SB-649868, antagonism at both
receptors tended to increase with time, although the increase was
greater at OX1R.
DISCUSSION
A thorough exploration of the pharmacokinetics and pharmaco-
dynamics of drug candidates is important in drug development.
Ideal sleep-enabling compounds have distinct profiles: rapid
absorption and induction of sleep, low blood drug concentra-
tions 8 h after dosing and efficacy in the absence of side effects
(Wilson et al., 2010). Understanding the nuances of the kinetics
of binding, such as the time taken to reach binding equilibrium,
can provide valuable predictive information on duration of action
and explain efficacy in patients.
With this inmindwe sought to characterize the kinetic features
of various “dual” orexin receptor antagonists at OX1R and OX2R.
We selected antagonists that have either been used clinically or
are currently under development for the treatment of insomnia
and sleep disorders, including almorexant, SB-649868, suvorex-
ant, and filorexant. We compared the kinetic features of these
compounds with those of BBAC (a fast binding dual orexin recep-
tor antagonist that was also used as a radioligand in the present
studies) and IPSU, an OX2R antagonist (see Betschart et al., 2013;
Hoyer et al., 2013). Our results show clearly that each of the lig-
ands tested has different properties at both OX1R and OX2R,
especially with respect to kinetics and suggest that at steady state
each of these compounds has a pharmacological profile different
from that measured under non-equilibrium conditions.
We observed that the radioligand [3H]-BBAC binds with high
affinity, rapidly and reversibly to both OX1R and OX2R. In com-
petition assays, unlabeled BBACwas a fast dual receptor binder, as
illustrated by competition curves which are virtually superimpos-
able irrespective of receptor type or incubation time. The slight
shift to the right as time increased indicates the concentration
dependence of the association rate, since the concentrations of
unlabeled ligand used in the competition experiments (Figure 3;
up to 10μM) are higher than those used for the radioligand (low
nM). This suggests unlabeled BBAC reaches apparent equilibrium
faster than [3H]-BBAC.
For the dual orexin receptor antagonists tested, time-
dependent changes in the apparent affinities for the receptors
www.frontiersin.org December 2013 | Volume 7 | Article 230 | 5
Callander et al. Kinetics of orexin receptor antagonists
Table 1 | Ca2+ signaling in cells stably transfected with human (CHO), rat (HEK) or mouse (HEK) OX1R in the presence of the endogenous
agonist (orexin A) or putative dual orexin receptor antagonists (almorexant, filorexant, suvorexant, SB-649868, and IPSU).
OX1R
30min 1h 2h 4h
pKi s.e.m. n pKi s.e.m. n pKi s.e.m. n pKi s.e.m. n
HUMAN
Orexin A 9.52 0.10 3 9.48 0.01 541 9.51 0.07 3 9.63 0.10 3
Almorexant 7.84 0.05 6 7.73 0.06 26 7.75 0.07 6 7.75 0.07 6
Filorexant 8.65 0.09 6 8.79 0.08 12 8.78 0.11 6 8.55 0.06 6
Suvorexant 8.39 0.09 6 8.74 0.10 8 8.75 0.12 6 8.73 0.15 6
SB-649868 9.03 0.05 6 8.87 0.09 12 9.29 0.08 6 9.38 0.10 6
IPSU 6.32 0.08 6 6.29 0.05 6 6.28 0.09 6 6.14 0.08 6
RAT
Orexin A 8.92 0.08 3 9.01 0.09 3 9.01 0.05 3 8.86 0.09 3
Almorexant 7.90 0.06 6 7.90 0.07 6 7.95 0.08 6 7.76 0.08 6
Filorexant 9.12 0.13 6 9.21 0.18 6 9.30 0.17 6 8.92 0.18 6
Suvorexant 8.82 0.20 6 9.40 0.36 6 9.37 0.19 6 9.24 0.17 6
SB-649868 9.59 0.11 6 9.90 0.19 6 10.17 0.10 6 10.14 0.06 6
IPSU 6.65 0.05 6 6.62 0.06 6 6.56 0.13 6 6.25 0.06 6
MOUSE
Orexin A 9.17 0.14 3 9.18 0.04 31 9.36 0.15 3 9.25 0.14 3
Almorexant 7.73 0.05 6 7.63 0.10 10 7.47 0.07 6 7.41 0.11 4
Filorexant 8.28 0.10 6 8.39 0.14 9 8.18 0.08 6 8.23 0.08 6
Suvorexant 8.90 0.14 6 8.98 0.18 4 9.03 0.08 6 8.99 0.08 6
SB-649868 9.80 0.12 6 9.37 0.14 7 10.39 0.16 6 10.33 0.17 6
IPSU 6.48 0.04 6 6.31 0.12 4 6.54 0.06 6 6.49 0.06 6
were found. The affinity of SB-649868 at hOX1R increased
markedly between 15min and 4 h, whilst time had little effect
on the affinity at hOX2R (Figure 5). The opposite is true for
almorexant, which displayed a leftward shift at hOX1R and a
very pronounced increase in affinity at hOX2R as incubation time
increased (Figure 4). Thus, SB-649868 and almorexant are slowly
equilibrating antagonists, presumably because their dissociation
rates are very slow. The data also suggests that when equilib-
rium is allowed to be reached, SB-649868 becomes somewhat
hOX1R selective, whereas almorexant becomes hOX2R selective.
The suvorexant competition curves demonstrated both hOX1R
and hOX2R have increasing affinity with time, although the effect
on hOX2R was somewhat less pronounced (Figure 6). Filorexant
shows somewhat different properties, in that equilibrium was
slow to be reached at hOX2R. By contrast, time had almost no
effect on the affinity of both BBAC and IPSU as measured in
the binding experiments. That is, the apparent affinity values
measured at 15min of incubation were at least as high as those
measured after 4 h, an indication that they reach steady state at
either receptor within a few minutes.
The time-dependent binding translated into differences in the
more functional FLIPR® calcium assay in whole cells expressing
human, rat, or mouse OX1 and OX2 receptors. Almorexant acted
as a pseudo-irreversible or very slowly equilibrating antagonist
at human, rat or mouse OX2R, whereas, at OX1R for all three
species, almorexant behaved as a fast equilibrating antagonist.
This data suggests that although originally described as a dual
antagonist with very similar affinity for both receptors, almorex-
ant is in fact a slowly equilibrating and somewhat selective OX2R
antagonist, if sufficient time is given for the ligand to reach equi-
librium. Similar findings were made in the calcium experiments
with suvorexant, SB-649868 and filorexant, indicating that all dis-
play slow equilibration at one and/or the other orexin receptor
(see Tables 1, 2). By contrast, IPSU (and BBAC) had constant
potency values irrespective of the incubation time, again suggest-
ing very fast equilibration at both orexin receptors. On the basis
of both the radioligand binding and calcium accumulation data
presented here, almorexant is likely to be OX2R selective, a find-
ing that is in agreement with other reports that found almorexant
to behave as a dual antagonist only during short incubation times
(Malherbe et al., 2009; Mang et al., 2012; Morairty et al., 2012). In
addition, we demonstrate in contrast to almorexant, SB-649868,
suvorexant, and filorexant have a greater affinity for OX1R with
long incubation times.
The differences in binding kinetics between the orexin recep-
tor antagonists demonstrated here are likely to have implications
for pharmacodynamics. Suvorexant is a pertinent example: stud-
ies of pharmacokinetics revealed a long dose-dependent apparent
terminal half-life (between 9 and 12 h, Merck Sharp and Dohme
Corporation, 2013a) and next morning residual effects (Sun
et al., 2013). It is possible that these residual effects are not only
related to half-life, but also longer than expected target/exposure
engagement. In addition, the suggestion that suvorexant has a
tendency to accumulate after 4 weeks of consecutive treatment is
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Table 2 | Ca2+ signaling in cells stably transfected with human (CHO), rat (HEK) or mouse (HEK) OX2R in the presence of the endogenous
agonist (orexin A) or putative dual orexin receptor antagonists (almorexant, filorexant, suvorexant, SB-649868, and IPSU).
OX2R
30min 1h 2h 4h
pKi s.e.m. n pKi s.e.m. n pKi s.e.m. n pKi s.e.m. n
HUMAN
Orexin A 8.76 0.05 3 8.79 0.01 548 8.61 0.07 3 8.70 0.02 3
Almorexant 8.33 0.05 6 8.82 0.06 29 8.80 0.15 6 9.09 0.22 6
Filorexant 9.45 0.09 6 9.65 0.06 11 9.73 0.10 6 9.77 0.09 6
Suvorexant 9.00 0.14 6 9.48 0.14 8 9.46 0.19 6 9.53 0.20 6
SB-649868 9.52 0.05 6 9.43 0.09 15 9.77 0.03 6 9.82 0.05 6
IPSU 8.00 0.10 6 7.97 0.07 6 7.82 0.08 6 7.68 0.11 6
RAT
Orexin A 8.40 0.01 3 8.34 0.07 6 8.48 0.06 3 8.58 0.03 3
Almorexant 8.25 0.08 6 8.65 0.06 6 8.99 0.19 6 9.18 0.10 6
Filorexant 9.13 0.11 6 9.38 0.08 6 9.60 0.11 6 9.75 0.10 6
Suvorexant 8.71 0.19 6 9.06 0.18 6 9.22 0.20 6 9.37 0.22 6
SB-649868 9.34 0.06 6 9.50 0.05 6 9.81 0.07 6 9.85 0.05 6
IPSU 7.63 0.14 6 7.55 0.11 6 7.62 0.12 6 7.55 0.11 6
MOUSE
Orexin A 8.78 0.07 3 9.05 0.02 53 8.94 0.01 3 9.18 0.02 3
Almorexant 7.72 0.06 5 8.03 0.05 14 8.09 0.05 6 8.38 0.05 6
Filorexant 8.67 0.13 6 8.68 0.06 9 8.84 0.10 6 8.89 0.11 6
Suvorexant 7.99 0.11 6 8.17 0.14 4 8.24 0.11 6 8.35 0.08 6
SB-649868 8.74 0.07 6 8.55 0.08 7 8.93 0.06 6 9.04 0.04 6
IPSU 7.15 0.04 6 7.10 0.09 4 7.26 0.06 6 7.22 0.07 6
not surprising (Farkas, 2013) given 24 h following administration
of a single dose, mean plasma levels of suvorexant remain between
0.1 and 0.6μM (Sun et al., 2013). These results may be explained
by a combination of pharmacokinetic effects (slow elimination
ormetabolism) and pharmacodynamic effects (slow equilibration
and off rates), as shown in the present studies.
The Food and Drug Administration (FDA, USA) have con-
cluded that although suvorexant is efficacious, it is not considered
safe at doses higher than 20mg (Farkas, 2013). The key safety
concerns raised were rapid onset daytime somnolence, motor
impairment, driving impairment, unconscious night time activity
such as sleep walking, suicidal ideation, hypnogogic hallucina-
tions and effects resembling mild cataplexy (Farkas, 2013; Radl,
2013; Sun et al., 2013). All of these appeared to be dose and
plasma-exposure dependent. In addition, the FDA suggested an
effort to find the lowest effective dose may be warranted (Farkas,
2013). Merck has determined that additional clinical studies are
not necessary for the 10mg dose, however, may be required to
support a 5mg dose (Farkas, 2013; Merck Sharp and Dohme
Corporation, 2013b).
The individual contribution of orexin receptors to sleep archi-
tecture is a matter of debate since, to our knowledge, no selective
OX1R or OX2R antagonist has been tested in patients with insom-
nia. However, rodent models are rather good predictors of the
effects of orexin receptor antagonists on sleep. In rodents, OX2R
antagonism appears sufficient to induce sleep: almorexant is
effective in the OX1R KO whereas it has no effect on the sleep
wake cycle in OX2R or in double receptor KO mice (Mang et al.,
2012). Further, in rodents with targeted destruction of the orexin
neurons of the lateral hypothalamus, treatment with almorexant
tends to induce cataplexy (Black et al., 2013). Nevertheless, there
are major differences relating to pharmacokinetics and pharma-
codynamics between species. One should also keep in mind that
whilst narcoleptic/cataplectic dogs have a defect in OX2R, this has
never been observed in humans.
In addition to almorexant, SB-649868 and suvorexant have
reached phase II clinical trials for the treatment of insomnia.
Clinical data suggests that the main effect on total sleep time is
largely due to an increase in REM sleep and decreased latency
to REM, with modest effects on non-REM or slow wave sleep,
if at all (Bettica et al., 2012a,c; Herring et al., 2012a,b; Hoever
et al., 2012). In the case of SB-649868, there is strong evidence
of sleep onset REM in patients receiving the 60mg dose (Bettica
et al., 2012a). Whilst no clinical evidence exists for filorexant,
recent rodent studies demonstrated the filorexant analog, DORA-
22, promotes sleep with dose-dependent increases in REM sleep
(Fox et al., 2013), suggesting that the mechanism may also be the
same for this compound.
Overall, the clinical data appears to confirm the preclinical
data collected in mice or rats which demonstrates dual orexin
receptor antagonists or dual receptor KOs induce sleep with a
very strong REM component, whereas OX2R KO or antagonism
has more balanced sleep phenotypes (Willie et al., 2003; Mang
et al., 2012; Betschart et al., 2013; Hoyer et al., 2013). Therefore,
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one may consider OX1R antagonism to be detrimental and sug-
gest that compounds such as suvorexant and SB-649868, which
show very slow kinetics at the OX1R, are likely to favor REM
over non-REM. For SB-649868, clinical studies in healthy vol-
unteers (Bettica et al., 2012b) and insomnia patients (Bettica
et al., 2012c) demonstrate that 10, 30, or 60mg SB-649868
decreases latency to REM and increases REM duration. In a 4
week placebo-controlled study of suvorexant in patients with
insomnia, Herring and colleagues observed that increases in
total sleep time were mainly due to increased time spent in
REM sleep (Herring et al., 2012b). Such compounds may also
increase rapid transitions between wake and REM states, espe-
cially if the compound is given a relatively long time before bed,
as was the case with SB-649868 (90min, Bettica et al., 2009a,
2012b).
Still, kinetics are of primary importance in sleep and an appro-
priate balance must be reached for therapeutic efficacy and safety.
If target occupancy is too short, the patient will wake up in the
middle of the night as happened with early formulations of Z
drugs such as zolpidem and zaleplon (Besset et al., 1995; Roth
et al., 1995; Greenblatt et al., 1998). Conversely, if target occu-
pancy is too long, there will be “hangover” effects into the next
morning, a crucial issue with benzodiazepine hypnotics (Wilson
et al., 2010). For compounds that have slow receptor kinetics,
pharmacodynamics and pharmacokinetics may not run in par-
allel, complicating their further development. The current report
suggests that all four established “dual” antagonists have very slow
kinetics, leading to changes in actual selectivity if equilibrium can
be reached in vivo; in addition, if equilibrium is reached, slow
off rates may result in longer receptor occupancy than may be
predicted solely from the pharmacokinetic data.
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